Study on the efficacy of empagliflozin in children with glycogen storage disease associated inflammatory bowel disease

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400080773

Enrollment

Unknown

Registered

2024-02-06

Start date

2022-07-01

Completion date

Unknown

Last updated

2024-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glycogen storage disease associated inflammatory bowel disease

Interventions

Experimental group:Empagliflozin

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: Meet the following 4 requirements: 1. Patients diagnosed with GSD associated IBD 2. Gender is not limited, the age is more than 2 years old 3. Patient's vital signs are stable 4. Voluntarily participate in the trial, and sign the informed consent form by himself or his legal guardian.

Exclusion criteria

Exclusion criteria: Meet 1 of the following: 1. Allergic to empagliflozin; 2. Patient's vital signs are unstable, or any disease or condition that may affect the conduct of the study or the interpretation of the results; 3. Active tuberculosis and malignant tumors; 4. Heart, liver, kidney and other organ dysfunction or failure 5. Participants who have participated in other studies or who are not considered suitable for inclusion by the investigator.

Design outcomes

Primary

Measure	Time frame
Endoscopic feature and SES-CD, and Geboes scores;	—

Secondary

Measure	Time frame
Disease Activity Index;Blood routine;Stool Routine;Blood biochemical;	—

Countries

China

Contacts

Public ContactYang Min

Guangdong Provincial People's Hospital

yangmin1008@gdph.org.cn+86 135 6010 1008

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026